IN8bio, Inc.

IN8bio, Inc.: IN8bio focuses on developing allogeneic, autologous and genetically modified gamma-delta T cells therapies for cancer treatments using its DeltEx Platform, based on ex-vivo expanded and activated gamma-delta T cells. First company to advance modified gamma-delta T cells into clinical trials. IN8bio has completed first cohort dosing for its two investigator-initiated Phase 1 clinical trials INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy, Gene Therapy
Website:
http://www.IN8bio.com
Address:
79 Madison Ave.
New York, NY 10016
United States
Presentation:
Please reach out to Solebury Strategic Communications to request a presentation
More info:
Send Message to Request Information
My account:
Log in or register to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Charles Butler, Vice President, Corporate Communications & Investor Relations
  • William T. Ho, President/CEO/Co-Founder

Top 10 Holders of IN8bio, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Voss Capital LLC 1.38 338,019 0.41 13F 12/31/22
Stonegate Investment Group LLC 0.95 232,310 0.28 13F 12/31/22
The Vanguard Group, Inc. 0.84 204,860 0.25 Funds 2/28/23
Vanguard Group, Inc. (Subfiler) 0.69 168,656 0.20 13F 12/31/22
Sigma Planning Corp. 0.40 99,150 0.12 13F 12/31/22
The Rock Creek Group LP 0.33 81,568 0.10 13F 12/31/22
Bridgeway Capital Management LLC 0.30 74,000 0.09 13F 12/31/22
Ensign Peak Advisors, Inc. 0.29 70,028 0.08 13F 12/31/22
Geode Capital Management LLC 0.24 58,665 0.07 13F 12/31/22
BlackRock Fund Advisors 0.12 29,568 0.04 13F 12/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.